Healthy Skepticism Library item: 14317
Warning: This library includes all items relevant to health product marketing that we are aware of regardless of quality. Often we do not agree with all or part of the contents.
Publication type: news
Sales Through Retail Pharmacies (Twelve months to July 2008)
IMS Health 2008 Sep 17
http://www.imshealth.com/deployedfiles/imshealth/Global/Content/StaticFile/Top_Line_Data/Retail_Drug_monitor_July.pdf
Full text:
Sales Through Retail Pharmacies (Twelve months to July 2008*)
NORTH AMERICA $224.6 billion up 3%
U.S.A. $207.4 billion up 1%
CANADA $17.2 billion up 6%
EUROPE (TOP 5) $116.8 billion up 3%
GERMANY $35.4 billion up 6%
FRANCE $31.6 billion up 3%
UK $17.0 billion down 1%
ITALY $17.4 billion up 1%
SPAIN $15.3 billion up 6%
JAPAN (including hospitals) $64.4 billion up 4%
LATIN AMERICA (TOP 3) $24.1 billion up 9%
BRAZIL $12.2 billion up 10%
MEXICO $8.8 billion up 5%
ARGENTINA $3.0 billion up 20%
AUSTRALIA/NZ $8.1 billion up 12%
The top 5 therapy classes at ATC3 level in the 12 months to July 2008
were:
1. C10A – Cholesterol & trigly. regulators
2. A2B – Antiulcerants
3. N6A – Antidepressants & mood stabilisers
4. N5A – Antipsychotics
5. N3A – Anti-epileptics
The top 5 products in the 12 months to July 2008 were:
1. Lipitor
2. Nexium
3. Plavix
4. Seretide/Advair
5. Enbrel
The top 5 corporations in the 12 months to July 2008 were:
1. Pfizer
2. GlaxoSmithKline
3. Novartis
4. AstraZeneca
5. Sanofi-Aventis
*Sales figures here cover direct and indirect pharmaceutical channel purchases (pharmacies plus hospital in Japan and mail order in the USA) from pharmaceutical wholesalers and manufacturers in 13 key global markets. Figures include prescription and certain over-the-counter data, and represent
manufacturer prices. These countries account for over two thirds of the world market.
These figures are taken from the monthly pharmaceutical audit conducted by IMS Health, the leading provider of healthcare information worldwide and cover the 12 month period indicated.
All sales values are shown in millions of dollars at prevailing exchange rates. In order to remove the effects of fluctuating exchange rates, growth rates are calculated net of exchange, in other words, growth figures are shown at local currency level or constant exchange except for the majority of the Latin America countries exclusive of Mexico, Chile, Colombia and Peru. In Argentina and Brazil sales are recorded in US dollars in Mexico – local currency. The unique system in Japan reduces the importance of the pharmacy in the distribution chain – sales reported include hospital data. In other countries sales monitored are limited to retail pharmacy only and do not include hospital data. In the USA our survey includes sales through mail order channels. Further details from the Media section of www.imshealth.com.
